sterna Biologicals GmbH & Co. KG is a clinical-stage immunology company developing novel treatments for type 2 chronic inflammatory diseases such as asthma and ulcerative colitis. By targeting GATA-3, a master transcription factor playing a central role in regulating Th1- and Th2-driven inflammatory mechanisms, sterna’s proprietary DNAzyme-based drug candidate hgd40 can intervene with upstream inflammatory processes to address related diseases more effectively. While existing treatment options often only address one inflammatory mediator, hgd40 broadly antagonizes several inflammatory processes and mediators at the same time.